DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for aneurysm-osteoarthritis syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAneurysm-osteoarthritis syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for aneurysm-osteoarthritis syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SMAD family member 3 (SMAD3) — SMAD3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1MK2 · 2.74 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The 2016 review of intra-articular therapies for osteoarthritis states that conventional treatments are palliative, aimed at pain and symptom control, and that traditional intra-articular therapies are not recommended as first-line therapy. It lists corticosteroids, hyaluronate, platelet rich plasma, and mesenchymal cell therapy as current or marketed options, and discusses interleukin-1β inhibitor, bone morphogenic protein-7, fibroblast growth factor 18, bradykinin B2 receptor antagonist, human serum albumin, and gene therapy as future directions. The review notes that the ability to demonstrate effect limits drug development, and that whether future therapies will provide clinically meaningful benefits remains unknown.
A 2021 study describes a drug delivery system for non-steroidal anti-inflammatory drugs (NSAIDs) using oil-in-water emulsions coated with poly-beta-amino-esters (PBAEs). The emulsions containing indomethacin, ketorolac, diclofenac, and naproxen showed enhanced and prolonged drug localisation in healthy and early-stage osteoarthritis cartilage samples. The PBAE layer on oil droplets was critical, and the technology prevented glycosaminoglycan and collagen degradation induced by interleukin-1. The authors call the system flexible and cost-effective, but no human data are presented.
A 2002 review of genetics and osteoarthritis notes that genetic mapping of Mendelian skeletal diseases can identify genes in joint homeostatic pathways, and that genetic studies in common osteoarthritis cohorts may identify genes for predisposition or progression. It mentions using the human transcriptome to study gene expression changes between normal and diseased tissues, and using mutations in other organisms to model disease. No specific genes or clinical applications are given.
No abstract directly addresses aneurysm-osteoarthritis syndrome. The 2016 review explicitly states that whether novel intra-articular therapies will provide clinically meaningful benefits remains unknown. The 2021 study is preclinical, with no patient outcomes. The 2002 review offers no therapeutic intervention. What is missing for any drug to be considered for this syndrome is a clear molecular target, a relevant animal model, patient stratification by genotype, and funding for a clinical trial that would test a specific compound in the defined patient population.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Pharmacotherapy · 2016 · 39 citations
Intra-articular therapies for osteoarthritis
AbstractINTRODUCTION: Conventional medical therapies for osteoarthritis are mainly palliative in nature, aiming to control pain and symptoms. Traditional intra-articular therapies are not recommended in guidelines as first line therapy, but are potential alternatives, when conventional therapies have failed. AREAS COVERED: Current and future intra-articular drug therapies for osteoarthritis are highlighted, including corticosteroids, hyaluronate, and more controversial treatments marketed commercially, namely platelet rich plasma and mesenchymal cell therapy. Intraarticular disease modifying osteoarthritis drugs are the future of osteoarthritis treatments, aiming at structural modification and altering the disease progression. Interleukin-1β inhibitor, bone morphogenic protein-7, fibroblast growth factor 18, bradykinin B2 receptor antagonist, human serum albumin, and gene therapy are discussed in this review. The evolution of drug development in osteoarthritis is limited by the ability to demonstrate effect. High quality trials are required to justify the use of existing intra-articular therapies and to advocate for newer, promising therapies. EXPERT OPINION: Challenges in osteoarthritis therapy research are fundamentally related to the complexity of the pathological mechanisms of osteoarthritis. Novel drugs offer hope in a disease with limited medical therapy options. Whether these future intra-articular therapies will provide clinically meaningful benefits, remains unknown.
Journal of Materials Chemistry B · 2021 · 11 citations · open access
Poly beta amino ester coated emulsions of NSAIDs for cartilage treatment
AbstractDelivering drugs directly into cartilage is still the major challenge in the management and treatment of osteoarthritis (OA) resulting from the aneural, avascular and alymphatic nature of an articular cartilage structure. Progress has been made in the design of drug delivery systems that enhance corticosteroid uptake and retention in cartilage; however also non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for patients affected by OA and a drug delivery system specifically designed for this drug category is currently unavailable. We developed an approach based on the preparation of NSAID oil-in-water emulsions coated with poly-beta-amino-esters (PBAEs) to exploit the cartilage penetrating ability of such polymers and the high solubility of drugs in oil. These emulsions containing different NSAIDs (indomethacin, ketorolac, diclofenac and naproxen) exhibited enhanced and prolonged drug localisation not only in healthy cartilage tissues but also in early-stage OA samples. The critical role of the PBAE layer on oil droplets was established along with the retained biological activity of the drug as glycosaminoglycan (GAG) and collagen degradation induced by interleukin-1 (IL-1) was prevented by the novel technology. Oil-in-water coated emulsions are very flexible and cost-effective drug delivery systems and such an approach presented here could provide a substantial improvement in the therapeutic treatments of OA and thus patients' outcomes.
AbstractGenetic approaches complement other approaches for gaining insights about the pathogenesis of osteoarthritis. Genetic mapping of simple Mendelian skeletal diseases can identify genes that participate in normal joint homeostatic pathways. Genetic studies in cohorts of patients having common forms of osteoarthritis will be more challenging, but may also identify genes that contribute to osteoarthritis predisposition and/or disease progression. Employing the entire human transcriptome to study changes in gene expression between normal and diseased tissues, or cells, can identify other participants in these complex pathways. Finally, naturally occurring mutations, or induced genetic variations, in other organisms can be used to model human disease phenotypes and further dissect the processes responsible for disease pathogenesis.
International Journal of Oral Health Dentistry · 2023 · 0 citations · open access
RFQMR- The future of myofunctional appliance
AbstractThe review attempts to suggest the use of Rotational Field Quantum Magnetic Resonance (RFQMR) beams in the treatment of skeletal class II cases with retrognathic mandible. A systematic electronic search was conducted in databases such as Google Scholar and PubMed. The inclusion and exclusion criteria were listed out and those publications that did not meet one or more of the inclusion criteria were excluded. A total of 40 articles were selected by search strategies. Out of which 3 studies matched with the inclusion criteria. The results of the 3 included studies were analysed. This review reveals that this non-surgical and non-invasive therapy is a landmark treatment for osteoarthritis. Its usage in the treatment of skeletal class II has to be time tested and proven.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
